2021 IPO

Impel NeuroPharma Stock

Medical device company developing a direct nose-to-brain delivery

Sign up today and learn more about Impel NeuroPharma Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Impel NeuroPharma Stock

Impel NeuroPharma is a medical device company developing a novel drug delivery device that enables drugs to bypass the blood-brain barrier(BBB) using direct nose-to-brain delivery.

Funding History

January 2010$305K
October 2011$500K
August 2012$25K
November 2013$2.6M
October 2015$0
August 2016$1.1M
December 2016$36.0M
December 2018$67.5M

Management

Chief Business Officer

Richard Haiduck

Director of R&D

Alan Brunelle

Co-Founder & CEO

Michael Hite

Co-Founder & Chief Scientific Officer

John Hoekman

President & CEO

Jon Congleton

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo